Age-Related Macular Degeneration (AMD) is a progressive eye condition that affects millions of people worldwide, leading to vision impairment and even blindness. Among its two main subtypes, Dry AMD is the more prevalent form, accounting for about 80% of all AMD cases. In this blog, we will delve into the symptoms of Dry AMD, explore the companies actively engaged in the Dry AMD market, and discuss the exciting developments in Dry AMD treatment.

What are Dry AMD symptoms?

Dry AMD, also known as non-neovascular or atrophic AMD, typically progresses slowly and often goes unnoticed until significant vision impairment occurs. Some common symptoms of Dry AMD include:

1. Blurred Vision: Patients may experience blurry central vision, making it difficult to recognize faces, read, or drive.

2. Difficulty Seeing in Low Light: Dry AMD can cause decreased night vision and difficulty adapting to dimly lit environments.

3. Visual Distortions: Straight lines may appear wavy or distorted, which can be a sign of macular damage.

4. Reduced Color Perception: Colors may seem less vibrant, and it may become challenging to distinguish between shades.

5. Difficulty Recognizing Faces: Identifying faces becomes increasingly challenging due to central vision loss.

Which companies are working in the Dry AMD market?

Several pharmaceutical and biotech companies are actively researching and developing treatments for Dry AMD. Among them, some notable Dry Amd Companies include:

1. Genentech/Roche: Genentech and Roche have been at the forefront of Dry AMD research with their investigational drug faricimab, which has shown promising results in clinical trials.

2. Novartis: Novartis is also actively involved in Dry AMD research, working on potential treatments to slow down the progression of the disease.

3. Regeneron Pharmaceuticals: Regeneron has been working on Eylea (aflibercept) as a potential treatment for Dry AMD.

4. Graybug Vision: Graybug Vision is developing innovative therapies for AMD, including wet and dry forms.

5. Apellis Pharmaceuticals: Apellis is exploring complement inhibitors as a treatment option for Dry AMD in clinical trials.

Dry AMD Market and Pipeline

The Dry AMD market is witnessing significant growth as research and development efforts continue to advance. Clinical trials are essential in evaluating potential treatments, and many promising candidates are in the pipeline. These trials aim to address unmet medical needs and improve the quality of life for Dry AMD patients.

Dry AMD Treatment: A Glimpse into the Future

The Dry AMD treatment landscape is evolving rapidly, with promising candidates offering hope for patients. These treatments primarily focus on slowing the progression of the disease, preserving vision, and enhancing patients’ overall quality of life. While there is currently no cure for Dry AMD, ongoing research and clinical trials hold the potential to revolutionize how we manage and treat this prevalent eye condition.

In conclusion, Dry AMD, a subtype of Age-Related Macular Degeneration, presents challenges for millions of individuals worldwide. However, advancements in research and development by leading pharmaceutical and biotech companies offer hope for better treatment options in the future. By staying informed about Dry AMD symptoms, market developments, and treatment prospects, we can collectively work towards improving the lives of those affected by this condition.

Latest Reports Offered By DelveInsight

Coagulation Analyzers Market

Coagulation Analyzers Market By Product Type (Instruments [Automated Analyzers, Semi-Automated Analyzers, And Manual Analyzers] And Reagents And Consumables), Test Type (Fibrinogen Testing, Activated Clotting Time Testing, D-Dimer Testing, Prothrombin Time, And Others), Technology (Optical Technology, Mechanical Technology, Electrochemical Technology, And Others), End-User (Hospitals, Diagnostic Centers, And Others), and geography is expected to grow at a steady CAGR forecast till 2028

Hemoconcentrators Market

Hemoconcentrators Market By Product Type (Pediatric Hemoconcentrators And Adult Hemoconcentrators), By End-User (Hospitals And Ambulatory Surgical Centres), and by geography is estimated to register a growth at a remarkable CAGR forecast during 2023-2028 owing to a surge in the cases of cardiovascular diseases and growing burden of geriatric population globally

Spinal Stenosis Devices Market

Spinal Stenosis Devices Market By Product Type (Interspinous Spacers, Stabilization Systems, Spinal Arthroplasty Systems, And Interbody Fusion Devices), By Application (Lumbar Spinal Stenosis, Cervical Spinal Stenosis, And Thoracic Spinal Stenosis), By End-User (Hospitals, Ambulatory Surgical Centres, And Others), and by geography is estimated to register a growth at a remarkable CAGR forecast during 2023-2028 owing to increasing prevalence of spinal stenosis and rising burden of geriatric population.

Ocular Implants Market

Ocular Implants Market By Type (Intraocular Lenses, Corneal Implants, Glaucoma Implants, Artificial Iris, And Others) By Material (Biodegradable And Non-Biodegradable), By Application (Cataract, Glaucoma Surgery, Oculoplasty, Drug Delivery, Macular Degeneration, And Others), By End-User (Hospitals, Eye Speciality Clinics, And Ambulatory Surgical Centres) and by geography is estimated to register a growth at a remarkable CAGR forecast during 2023-2028 owing to surge in the cases of various eye disorders and growing burden of geriatric population globally

Carpal Tunnel Release System Market

The Carpal Tunnel Release System Market By Type (Endoscopic Carpal Tunnel Release System And Open Carpal Tunnel Release System), By End-User (Hospitals, Ambulatory Surgical Centres, And Others), and by geography is estimated to register a growth at a remarkable CAGR forecast during 2023-2028 owing to rising cases of workplace associated carpal tunnel syndrome and increasing prevalence of carpal tunnel syndrome among women.

Related Reports by DelveInsight-

Recent Blog’s By DelveInsight:

Medtechnews

Tag: Dry AMD Pipeline